Zacks Investment Research·1 day ago
Here's Why Quest Diagnostics (DGX) is a Strong Momentum StockWondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Quest Diagnostics Incorporated(DGX)Earnings, Financials & Key Ratios
DGX•NYSE
$212.38
24.3× P/E·Price updated Jul 7, 2026
AboutQuest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.Show more
- Revenue$11.04B+11.8%
- EBITDA$2.17B+18.2%
- Net Income$992M+13.9%
- EPS (Diluted)8.75+13.8%
- Gross Margin31.93%-2.8%
- EBITDA Margin19.69%+5.7%
- Operating Margin14.53%+6.5%
- Net Margin8.99%+1.9%
- ROE13.99%+6.9%
DGX Price & Volume
Quest Diagnostics Incorporated (DGX) stock price & volume — 10-year historical chart
Loading chart...
Inorganic Growth Strategy Drives Diagnostic Revenue Expansion
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Accelerating
Profitability:Moderate
Financial:Healthy
Cash Flow:Mixed
Primary Risk:Reimbursement and PAMA pressure
Key Thesis Takeaways
- Quest Diagnostics is leveraging a consistent acquisition-led strategy to drive top-line growth, evidenced by a 9.2% year-over-year revenue increase in 2026Q1.
- While the company maintains a stable operating margin of 13.8%, investors should monitor the heavy reliance on goodwill, which now comprises 54% of total assets, and the potential for margin compression due to persistent reimbursement pressures.
- Future performance will likely depend on the successful integration of acquired laboratory networks and the ability to manage a debt-to-equity ratio of 0.91 in a volatile diagnostic volume environment.
Verdict Logic
while the company shows resilient revenue growth of 9.2%, the current P/E of 23.99 and the high concentration of goodwill at 54% of total assets warrant a cautious approach.
DGX Growth Metrics
Quest Diagnostics Incorporated (DGX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years3.95%
5 Years3.18%
3 Years3.74%
TTM11.03%
Profit CAGR
10 Years3.42%
5 Years-7.07%
3 Years1.6%
TTM14.16%
EPS CAGR
10 Years6.03%
5 Years-3.62%
3 Years3.12%
TTM14.27%
Return on Capital
10 Years13.22%
5 Years12.92%
3 Years10.83%
Last Year11.48%
DGX Recent Earnings
Quest Diagnostics Incorporated (DGX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 12/12 qtrs (100%)●Beat Revenue 12/12 qtrs (100%)
Q2 2026Latest
Apr 21, 2026Metric
Actual
Est
EPS
$2.50+5.5%
$2.37
Rev
$2.9B+2.3%
$2.8B
Q1 2026
Feb 10, 2026Metric
Actual
Est
EPS
$2.42+2.5%
$2.36
Rev
$2.8B+1.9%
$2.8B
Q4 2025
Oct 21, 2025Metric
Actual
Est
EPS
$2.60+4.0%
$2.50
Rev
$2.8B+2.9%
$2.7B
Q3 2025
Jul 22, 2025Metric
Actual
Est
EPS
$2.62+1.9%
$2.57
Rev
$2.8B+1.3%
$2.7B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 21, 2026 | $2.50vs $2.37+5.5% | $2.9Bvs $2.8B+2.3% |
| Q1 2026 | Feb 10, 2026 | $2.42vs $2.36+2.5% | $2.8Bvs $2.8B+1.9% |
| Q4 2025 | Oct 21, 2025 | $2.60vs $2.50+4.0% | $2.8Bvs $2.7B+2.9% |
| Q3 2025 | Jul 22, 2025 | $2.62vs $2.57+1.9% | $2.8Bvs $2.7B+1.3% |
Based on last 12 quarters of dataView full earnings history →
Latest DGX News
Recent stock market news and headlines for Quest Diagnostics Incorporated (DGX)
Zacks Investment Research·5 days ago
Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run?Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks Investment Research·Jun 25, 2026
DGX's Stock Rises on Haystack MRD Test's Approval From NYSDOHQuest Diagnostics gains NYSDOH approval for Haystack MRD, expanding the cancer test to all 50 states and strengthening its oncology reach.
GuruFocus·Jun 24, 2026
Quest Diagnostics Inc (DGX) Stock Up 3.0% but GF Value Says Overvalued -- GF Score: 83/100On June 24, 2026, Quest Diagnostics Inc (DGX) shares rose 3.0% today, currently trading at $203.11. This performance places the stock well within its 52-week ra
PRNewsWire·Jun 24, 2026
Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease TestingAchieving the rigorous laboratory standard broadens access for providers and patients in New York; applies to use of Haystack MRD for patients with solid tumor cancers SECAUCUS, N.J., June 24, 2026 /PRNewswire/ -- Quest Diagnostics® (NYSE: DGX), a leading provider of diagnostic information services, today announced that the New York State Department of Health's (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) has approved the company's Haystack MRD® test, a circulating tumor DNA (ctDNA) liquid biopsy test, for use in identifying residual or recurring disease in patients with a range of solid tumor cancers.
Peers Comparison
Key metrics vs top competitors for Quest Diagnostics Incorporated (DGX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $212.38 | $23.51B | 24.27 | 11.78% | 8.99% | 13.99% | 1.47% | |
| $283.86 | $23.36B | 27.14 | 7.25% | 6.66% | 10.89% | — | |
| $53.01 | $2.76B | 135.92 | — | 33.7% | 22.86% | — | |
| $104.91 | $20.02B | -95.37 | 17.69% | -6.4% | -8.66% | — | |
| $292.50 | $7.9B | 10.50 | 0.65% | 6.52% | 2.4% | — | |
| $9.39 | $2.04B | -1.87 | -3.2% | -69.93% | -29% | — |
Compare DGX vs Peers
Quest Diagnostics Incorporated (DGX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DGX SEC Filings & Documents
Quest Diagnostics Incorporated (DGX) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
Apr 21, 2026·SEC
Material company update
Mar 12, 2026·SEC
Material company update
Feb 10, 2026·SEC
10-K Annual Reports
210-Q Quarterly Reports
6Get notified when DGX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DGX Frequently Asked Questions
Quest Diagnostics Incorporated (DGX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Quest Diagnostics Incorporated's revenue?
Quest Diagnostics Incorporated (DGX) reported $11.28B in revenue for fiscal year 2025. This represents a 598% increase from $1.62B in 1996.
How fast is Quest Diagnostics Incorporated growing?
Quest Diagnostics Incorporated (DGX) grew revenue by 11.8% over the past year. This is steady growth.
Is DGX profitable?
Yes, Quest Diagnostics Incorporated (DGX) is profitable, generating $1.02B in net income for fiscal year 2025 (9.0% net margin).
Dividend & Returns
Does DGX pay dividends?
Yes, Quest Diagnostics Incorporated (DGX) pays a dividend with a yield of 1.47%. This makes it attractive for income-focused investors.
What is DGX's return on equity?
Quest Diagnostics Incorporated (DGX) has a return on equity (ROE) of 14.0%. This is reasonable for most industries.
What is Quest Diagnostics Incorporated's free cash flow?
Quest Diagnostics Incorporated (DGX) generated $1.33B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.